Keyword: Henri Termeer

News

Sanofi Likely to Extend $18.5 Billion Tender Offer for Genzyme

20.01.2011 - French drugmaker Sanofi-Aventis is likely to extend its $18.5 billion tender offer for Genzyme one last time as it seeks to buy the U.S. maker of drugs for rare diseases, sources...

News

Genzyme Posts Disappointing Q4 Results; Refuses to Comment on Sanofi

12.01.2011 - Genzyme, the subject of an $18.5 billion hostile takeover bid from Sanofi-Aventis SA, posted preliminary Q4 earnings that fell short of Wall Street forecasts and cut its earnings...

News

Genzyme Acknowledges Sanofi Talks, Quick Deal Hopes Cool

11.01.2011 - Genzyme acknowledged on Monday that it was discussing a takeover deal with French drugmaker Sanofi-Aventis, but hopes for a quick agreement cooled as both sides noted differences...

News

Sanofi Considering Raising Bid for Genzyme

10.01.2011 - French drugmaker Sanofi-Aventis and Genzyme Corp are discussing options for significantly raising Sanofi's bid for the the U.S. biotech company to about $80 per share, the Wall...

News

Chris Viehbacher, Henri Termeer Get Close But Will They Talk?

07.01.2011 - Could it be time to talk in the long-running saga of Sanofi-Aventis $18.5 billion bid for Genzyme Corp? There is certainly the opportunity. The two chief executives at the center...

News

Genzyme Argues Campath Value In Sanofi Fight

21.12.2010 - Genzyme argued that its experimental multiple sclerosis treatment will garner far higher sales than Sanofi-Aventis is projecting, as it aims to wrest a significantly higher bid...

News

Ralph Whitworth:Right Sanofi Price 'Lots Higher'

06.12.2010 - Genzyme shareholder and board member Ralph Whitworth said the "ingredients are there" for a deal with Sanofi-Aventis , but the French drugmaker's $69-a-share offer is "not even a...